FLT3LG and neoplasm: The NSG and NSG-A2 mice bearing orthotopically injected MDA-MB-231 triple-negative breast cancer cells were humanized with HLA-A*02+ PBMC 6 days after tumor cell injection (d0) and boosted with two injections of Flt3-L-treated autologous PBMCs on days 9 and 16 (Figure 4B).